Kim Hemsley

Prof. Kim Hemsley


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2017 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
LWLauren S. Whyte
Lauren S. Whyte
ALAdeline Lau
Adeline Lau
KHKim Hemsley
Kim Hemsley
JHJohn J. Hopwood
John J. Hopwood
TSTimothy J Sargeant
Timothy J Sargeant

1 August 2006 in Brain Research
Verified
Journal Article
Closed access
ACAllison C. Crawley
Allison C. Crawley
BGBriony L. Gliddon
Briony L. Gliddon
DADyane Auclair
Dyane Auclair
SBSuzanne L. Brodie
Suzanne L. Brodie
CHCraig Hirte
Craig Hirte
JHJohn J. Hopwood
John J. Hopwood

27 August 2007 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
AFAlessandro Fraldi
Alessandro Fraldi
KHKim Hemsley
Kim Hemsley
ACAllison Crawley
Allison Crawley
ALAlessia Lombardi
Alessia Lombardi
ALAdeline Lau
Adeline Lau
JHJohn J. Hopwood
John J. Hopwood
Mucopolysaccharidosis type IIIA (MPS-IIIA or Sanfilippo syndrome) is a lysosomal storage disorder caused by the congenital deficiency of sulfamidase (SGSH) enzyme and consequent accumulation of partially degraded heparan sulfate (HS) in lysosomes. The central nervous system (CNS) is the predominant site of tissue damage in MPS-IIIA. Here we describe a gene therapy approach for MPS-IIIA in a mouse model using recombinant adeno-associated virus serotype 5 (AAV2/5) as a vehicle to deliver therapeutic genes to the CNS. SUMF1 (SUlfatase Modifying Factor 1) exhibits an enhancing effect on sulfatase activity when co-expressed with sulfatases. Consistent with these findings, we demonstrated that co-delivery of SUMF1 and SGSH (via an AAV2/5-CMV-SGSH-IRES-SUMF1 vector) resulted in a synergistic increase in SGSH activity, both in primary neural cells and in murine brain. A study aimed at testing the therapeutic efficacy of simultaneous brain administration of SUMF1 and SGSH was then performed by injecting the lateral ventricles of newborn MPS-IIIA/normal mice with either AAV2/5-CMV-SGSH-IRES-SUMF1 or AAV2/5-CMV-GFP vectors. Widespread GFP expression was observed within the GFP-injected brain, and a stable and significant increase of SGSH activity was detected in several brain regions following SGSH-IRES-SUMF1 administration. Treatment with AAV2/5-CMV-SGSH-IRES-SUMF1 vectors resulted in a visible reduction in lysosomal storage and inflammatory markers in transduced brain regions. Finally, the MPS-IIIA mice treated with therapeutic genes displayed an improvement in both motor and cognitive functions. Our results suggest that early treatment of CNS lesions by AAV-mediated intraventricular injection of both SGSH and SUMF1 genes may represent a feasible therapy for MPS-IIIA.

1 January 2018 in Behavioural Brain Research
Verified
Journal Article
Closed access
LWLauren S. Whyte
Lauren S. Whyte
KHKim Hemsley
Kim Hemsley
ALAdeline Lau
Adeline Lau
SHSofia Hassiotis
Sofia Hassiotis
TSTakashi Saito
Takashi Saito
TSTimothy J Sargeant
Timothy J Sargeant

1 March 2007 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
KHKim Hemsley
Kim Hemsley
BKBarbara King
Barbara King
JHJohn J. Hopwood
John J. Hopwood

30 March 2005 in Behavioural Brain Research
Verified
Journal Article
Closed access
KHKim Hemsley
Kim Hemsley
JHJ Hopwood
J Hopwood